Amicus Therapeutics, Inc.
FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, aā¦ read more
Healthcare
Biotechnology
17 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.40
Price+3.93%
$0.28
1Y
Price
Market Cap
$2.281b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-17.7%
EBITDA Margin-43.9%
Net Profit Margin-28.5%
Free Cash Flow MarginRevenue
$571.160m
+6.0%
1y CAGR+11.7%
3y CAGR+13.1%
5y CAGREarnings
-$38.096m
+3.0%
1y CAGR+14.8%
3y CAGR+13.5%
5y CAGREPS
-$0.12
+2.0%
1y CAGR+16.9%
3y CAGR+16.2%
5y CAGRBook Value
$204.304m
$815.303m
Assets$610.999m
Liabilities$443.315m
DebtDebt to Assets
54.4%
-6x
Debt to EBITDAFree Cash Flow
$1.608m
-15.0%
1y CAGR+19.2%
3y CAGR+17.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company